Abstract:
Summary.
A frequent and hazardous complication of endstage renal diseases ESRD is anemia. In our study
we administered recombinant human erythropoietin (Eprex), Epoetin-, Janssen Cilag, to 65 anemic
patients with ESRD, who were undergoing hemodialysis. Eprex was given subcutaneously three times
weekly after dialysis, and Ht, Er, Hb; predialysis levels of creatinine and blood urea nitrogen, blood
protein level, ferrokinetics, and blood pressure were monitored. Our results demonstrate that Eprex is
effective, can restore the Ht to normal in many patients with the need for transfusions with their risks
of immunologic sensitization and infection. The treatment with Eprex permit to include and maintain
the patients in the waiting list for transplantation in a good condition
